RecruitingLGLL - Large Granular Lymphocytic LeukemiaPrimary Cutaneous Gamma-Delta T-Cell LymphomaPrimary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Eligible age
18+ yrs
Accepts
All genders
Locations
11 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas
Sponsor: Dren Bio
You may qualify if…
- ✓ 1. ≥18 years of age.
- ✓ 2. Able to understand and comply with protocol-required study procedures and voluntarily sign a written informed consent document.
- ✓ 3. Sufficient key organ performance and coagulation.
- ✓ 4. Female subjects of childbearing potential (postmenarcheal, has an intact uterus and at least one ovary, and is \<1 year postmenopausal) must agree to use a highly effective method of contraception from enrollment through at least 12 months after last dose of DR-01.
- ✓ 5. Male subjects must agree to use acceptable effective method(s) of contraception.
- ✓ Subjects with LGLL must also meet inclusion criteria 6 and 7.
- ✓ 6. Must have discontinued at least one prior line of systemic therapy.
- ✓ 7. Additional immunophenotypic and symptomatic criteria must be met.
You may not qualify if…
- ✕ Disease-specific Exclusion Criteria; LGLL and ANKL:
- ✕ 1. A reactive LGL lymphocytosis to a viral infection or LGL associated with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
- ✕ The following exclusion criteria apply to all subjects:
- ✕ 2. Active systemic infection or severe localized infection requiring systemic antibiotics, antivirals or antifungals.
- ✕ 3. Active or suspected malignant central nervous system involvement.
- ✕ 4. Life-threatening, severe complications of malignancy (e.g., uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation).
- ✕ 5. Active known second malignancy.
- ✕ 6. Infection with human immunodeficiency virus (HIV) type 1 or 2 (HIV-1 or HIV-2).
Where it's recruiting
Alabama
Birmingham
California
Duarte · Irvine · Redwood City
Connecticut
New Haven
Florida
Tampa
Massachusetts
Boston
New York
New York
Ohio
Columbus
Pennsylvania
Pittsburgh
Texas
Houston
Virginia
Charlottesville · Fairfax
Washington
Seattle · Nedlands
Source: ClinicalTrials.gov · NCT05475925 · last updated 2026-06-17